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Background: The purpose of this study is to investigate the association of metabolic syndrome (MS) and its
components with the risk of impaired glucose tolerance (IGT) in high risk urban professionals. The goal is to
improve the selection of candidates who would most benefit from an oral glucose tolerance test (OGTT).
Methods: This is a cross sectional study in which MS was identified by both the definitions proposed by the
National Cholesterol Education Program (NCEP) and the International Diabetes Federation (IDF).
Results: There were 928 eligible subjects in the study, and 23.9% of them failed in OGTT. The odds ratio of IGT was
increased 3.16-fold for MS defined by the NCEP criteria and 2.79-fold for the hyperglycemia factor alone. Both MS
and hyperglycemia were shown to be acceptable measures to discriminate subjects with IGT from those with
normal glucose tolerance (NGT). The clustering of any 1, 2, or ≥3 metabolic components resulted in increased odds
ratios for IGT: i.e., 1.71, 2.38 and 5.92, respectively. Even without hyperglycemia in the cluster, an increased odds
ratio was still observed. The risk of IGT increased dramatically when the fasting plasma glucose and waist
circumference were both at their highest defined level.
Conclusions: MS and its components are associated with the increased risk of IGT. People with MS, one of its
components, especially hyperglycemia and central obesity, or a cluster of its components are strong candidates for
an OGTT in order to achieve early cost-effective detection of IGT.
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The prevalence of diabetes is rapidly increasing in China
and throughout the world [1-3]. Meanwhile, diabetes
often remains undiagnosed for a long period of time,
during which irreversible damage to multiple organs can
occur [4-9]. Although evidence is clear that early detec-
tion and intervention of diabetes play important roles in
diabetes control [10,11], there are still many challenges
in developing effective methods to identify high risk indi-
viduals as early as possible [4-6,12-16]. Of all the screen-
ing tests, a fasting glucose test is a comparatively simple
and pragmatic approach to assess the glycemic status of
an individual. However, there is increasing evidence that* Correspondence: ws3704@yahoo.com.cn
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reproduction in any medium, provided the orfasting glucose alone misses many persons who might fail
the more rigorous oral glucose tolerance test (OGTT)
[7-9,13-16], which is required to identify patients with im-
paired glucose tolerance (IGT). Most importantly, IGT
has been revealed to be a stronger predictor of future dia-
betes than impaired fasting glucose (IFG) [16-18]. Once
these patients are identified, lifestyle modification and
medication have been shown to prevent or delay the pro-
gression to diabetes [10,11]. However, the disadvantages of
OGTT – its inconvenience and cost – limit its use for
large-scale screening.
Metabolic syndrome (MS) has been proposed as pre-
diabetic status in various ethnic groups, and many studies
have confirmed the association between MS and the sub-
sequent development of diabetes [19-27]. In contrast,
fewer studies have investigated the association between
MS and the risk of IGT [4,6,27-29]. When compared totd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cumference (WC), blood pressure (BP), fasting plasma
glucose (FPG), high-density-lipoprotein-cholesterol (HDL-C)
and triglycerides (TG) levels – are far more widely gath-
ered during routine checkups. Therefore, given these cir-
cumstances, it is useful to evaluate the association
between MS and IGT cross-sectionally, in order to im-
prove the selection of candidates who would most bene-
fit from an OGTT. In China, however, the probability of
IGT given MS is usually underestimated by clinicians
when evaluating patients with normal fasting glucose
levels.
In this study, we assess the association of MS, as de-
fined by both the updated US National Cholesterol Edu-
cation Program (NCEP) Adult Treatment Panel III (ATP
III) [30] and the International Diabetes Federation (IDF)
[31], with the probability of IGT in a group of profes-
sionals in Beijing, China. We used both sets of criteria
because the IDF definition requires abdominal obesity as
the pre-condition for the diagnosis of MS. In contrast, the
NCEP criteria do not have this requirement, and therefore
it is more inclusive in the diagnosis of MS. We also ana-
lyzed the associations of individual components and their
clustering with the risk of IGT in this population.
Methods
Data collections
The study, approved by the Ethics Committee of Beijing
Hospital, Ministry of Health, was carried out in two re-
search institutes in Beijing. The interviewers were
trained before the survey was administered. The ques-
tionnaire was designed to collect information on demo-
graphics, lifestyle, history of diseases, and physical and
laboratory examination findings. Self-reported history of
type 2 diabetes (ever-diagnosed or currently taking
medicine to control glucose level), hypertension (ever-di-
agnosed, or taking medicine to control blood pressure),
and family history of diabetes and hypertension were
assessed. When the waist circumference (WC) was mea-
sured for central obesity, the subject stood, and the mea-
surement was made at the level of umbilicus at the end of
normal expiration. Blood pressures (BP) were measured
twice in a sitting position, and the mean values were used
in the assessment. Blood samples were taken after a fast
of at least 12 hours and were measured in the clinical
laboratory of Beijing Hospital, where the analyses were
calibrated by Cholesterol Reference Method Laboratory
Network (CRMLN) Member Laboratory (The Key La-
boratory of Geriatrics, Beijing Hospital & Beijing Insti-
tute of Geriatrics, Ministry of Health).
Definitions
After finishing their regular health examinations, the
volunteers consumed a standardized 75-g glucose load,and glucose levels were measured again 2 hours later.
IGT is defined as glucose level at 2 hours post-glucose
loading (2 hPG) from ≥7.8 mmol/l to <11.1 mmol/l [32].
Impaired fasting glucose (IFG) is defined as FPG levels
of 6.1-6.9 mmol/l [32].
The criteria for the components of MS were defined
as: 1. Central obesity: WC ≥90 cm for men and ≥80 cm
for women; 2. High triglyceride level: TG ≥1.70 mmol/l
(150 mg/dl), or under specific treatment for this lipid ab-
normality; 3. Low high-density-lipoprotein-cholesterol:
HDL-C <1.03 mmol/l (40 mg/dl) for men and <1.29 mmol/l
(50 mg/dl) for women or under specific treatment for this
lipid abnormality; 4. Elevated blood pressure: systolic
blood pressure (SBP) ≥130 mmHg, or diastolic blood pres-
sure (DBP) ≥85 mmHg, or having previously diagnosed
hypertension; 5. Hyperglycemia: fasting plasma glucose
(FPG) ≥5.6 mmol/l (100 mg/dl). The IDF criteria for MS
are central obesity plus ≥2 of the other four factors. The
NCEP ATP-III criteria are similar, except central obesity is
not a prerequisite, being defined simply as any three of
the five sub-optimal conditions above.
Subjects
In this study, persons aged ≥20 were invited to partici-
pate in this study when they took their annual health
examinations. There were 1242 informed consent vol-
unteers enrolled in the study, of whom 65% performed
office work, such as research; 7% worked in mainten-
ance and other areas; and 28% were retired. People
with known IGT or diabetes, or who were taking
medication for these conditions, or whose FPG levels
were ≥7.0 mol/l, or whose 2 hPG ≥11.1 mmol/l in this
examination were not included in the study, leaving a
total of 928 subjects.
Statistical analysis
The different characteristics of subjects in the group with
normal glucose tolerance (NGT) (2 hPG <7.8 mmol/l) and
those in the group with IGT were compared using one-
way ANOVA tests and Chi-square tests. Logistic regres-
sion was used in multivariable models to estimate the
adjusted odds ratios and 95% confidence interval (95% CI).
The area under the receiver-operating characteristic curves
(AROCs) was used to estimate the ability of MS or its
components to discriminate subjects with IGT from those
without IGT. The higher the AROC, the better the dis-
crimination. Attributable risk percentage (AR%) is the ex-
cess risk of IGT attributable to MS or its components.
Population attributable risk percentage (PAR%) is defined
as the excess rate of IGT in a population associated with
MS or its components. When the relationships between
the numbers of abnormalities and IGT were assessed, the
group without any disorders was set as the reference
group. The dummy variables were created for persons
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lyses were carried out using SAS software licensed to
Chinese Center for Disease Control and Prevention, and
p <0.05 was considered statistically significant.Results
The characteristics of the study subjects
The different characteristics of subjects with NGT (2
hPG < 7.8 mmol/l) and IGT are shown in Table 1. There
were a total of 928 eligible subjects (403 males and 525
females) without diagnosed diabetes who participated in
this study. 222 subjects (85 males and 137 females) were
found to have IGT. Persons with MS defined by both
IDF criteria and NCEP criteria had statistically higher
risk of presenting IGT than its reference group (that is,
those not meeting either the IDF or NCEP criteria of
MS): 58.1% vs. 25.5% for NCEP criteria, and 52.7% vs.
22.8% for IDF criteria. Also, the subjects with IGT
tended to be older and have higher values for WC, FPG,
TG, weight, BMI, systolic BP, diastolic BP and lower
HDL cholesterol. Unexpectedly, the risk of IGT was not
related to family history of diabetes nor educational
attainment less than 12 years.Table 1 Characterization of study subjects with normal
glucose tolerance (NGT) and impaired glucose
tolerance (IGT)a
NGTb IGTc p-value
(n = 706) (n = 222)
Gender 0.0767
Male (n = 403) 45.0 38.3
Female (n = 525) 55.0 61.7
Age 45 ± 15 57 ± 15 <0.0001
Waist circumference (cm) 83 ± 10 89 ± 9 <0.0001
Fasting glucose level (mmol/l) 5.17 ± 0.51 5.57 ± 0.52 <0.0001
2-h Post loading glucose
level (mmol/l)
6.15 ± 0.95 8.88 ± 0.92 <0.0001
Triglyceride (mmol/l) 1.50 ± 0.96 1.84 ± 1.02 <0.0001
HDL cholesterol (mmol/l) 1.34 ± 0.34 1.30 ± 0.33 0.1423
Weight (kg) 66 ± 13 67 ± 13 0.3205
Body mass index (kg/m2) 23.6 ± 3.6 24.8 ± 3.7 <0.0001
Systolic blood pressure (mmHg) 117 ± 15 126 ± 16 <0.0001
Diastolic blood pressure (mmHg) 78 ± 9 81 ± 10 0.0002
Family History of Diabetes 23.9 23.0 0.0868
Education (<12 years) 7.5 8.1 0.7689
MS NCEP criteria 25.5 58.1 <0.0001
MS IDF criteria 22.8 52.7 <0.0001
aData are mean ± SD, or n(%). HDL: high density lipoprotein; MS: metabolic
syndrome; NCEP: National Cholesterol Education Program; IDF: International
Diabetes Federation. bNGT: glucose level at 2 hours post-glucose loading
(2 hPG) <7.8 mmol/l; cIGT: impaired glucose tolerance.The association of impaired glucose tolerance with
metabolic syndrome and its components
The association of IGT with MS and individual compo-
nents of MS are shown in Table 2. Central obesity pre-
sented the highest prevalence rate (52.7%) and followed
by high blood pressure (44.7%) in this population. About
30% of the population displayed MS or any one of the
other metabolic components. The odds ratio of IGT
were increased 3.16-fold for MS, defined by the NCEP
criteria, 2.84-fold for MS, defined by the IDF criteria,
and 2.79-fold for the hyperglycemia factor, and all of
them had greater than 60% probability to discriminate
persons with IGT from persons without IGT. For AR%,
the risk of IGT was over 60% attributable to both MS
(by either definition) and hyperglycemia. For PAR%,
about one third of IGT in the population might be at-
tributable to MS (by either definition), hyperglycemia,
central obesity and high blood pressure. In contrast,
high TG and low HDL-C each had a lower association
with IGT.
The association of impaired glucose tolerance with the
clustering of metabolic components
The risk associations of the clustering of metabolic com-
ponents are shown in Table 3. The risk of IGT increased
as the number of metabolic components included in the
cluster increased. Although OR decreased a little when
hyperglycemia was excluded from the number of com-
ponents in the clustering, a rising risk gradient was still
observed. When the combinations of metabolic compo-
nents were analyzed, the clusters that included hypergly-
cemia exhibited the highest association with IGT. When
hyperglycemia was excluded from the clustering, the
combinations with central obesity showed the greatest
increased risk of IGT.
The effect of combining central obesity and
hyperglycemia on the risk of impaired glucose tolerance
The effect of combining WC and FPG on the risk of
IGT is shown in Table 4. The IGT risk increased with
increasing waist circumference and/or increasing fasting
glucose level. The risk of IGT increased dramatically
when both FPG and WC were present at their highest
levels.
Discussion
Type 2 diabetes has become a significant human health
disease threat across the globe. Although early detection
and intervention are recognized as the most important
and effective way to prevent or delay the onset of dia-
betes or its complications [7-11], data from the year
2000 showed that three out of four diabetes patients in
China were undiagnosed [2], and data from 2007 showed
that three out of five diabetes patients in China
Table 2 Association of IGT with the components of metabolic syndromea
Prevalence (%) Number of IGT (%) OR (95% CI) AROC (95% CI) AR % PAR %
MS-NCEP 309 (33.3) 129 (41.8) 3.16 (2.26-4.42) 63.4 (60.3-66.5) 64.0 37.2
MS-IDF 278 (30.0) 132 (42.1) 2.84 (2.03-3.97) 63.0 (60.0 -66.0) 61.6 32.5
Central obesity 489 (52.7) 158 (32.3) 2.06 (1.46-2.91) 58.9 (56.2-61.5) 54.9 39.1
Hyperglycemia 279 (30.1) 118 (42.3) 2.79 (1.99-3.91) 66.9 (61.5-72.3) 61.3 32.6
High TG 293 (31.6) 96 (32.8) 1.95 (1.39-2.74) 56.5 (53.4-59.6) 39.4 17.1
Low HDL-C 301 (32.4) 91 (30.2) 1.65 (1.19-2.30) 54.7 (51.6-57.7) 30.9 12.7
High BP 415 (44.7) 141 (34.0) 1.61 (1.13-2.30) 59.1 (56.3-62.9) 53.5 34.0
aLogistic regression was age-and gender-adjusted. IGT: impaired glucose tolerance; MS: metabolic syndrome; NCEP: National Cholesterol Education Program; IDF:
International Diabetes Federation; TG: triglycerides; HDL-C: high-density-lipoprotein cholesterol; BP: blood pressure; AROC: receiver-operating characteristic curve;
AR %: Attributable risk percentage; PAR %: Population attributable risk percentage.
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ings can be explained by the low rate of regular
checkups in general population in China. In our study,
the subjects could easily access regular health examin-
ation, and their fasting glucose levels were checked
annually. However, 23.9% of individuals still failed the
two-hour post challenge glucose test. In addition, previ-
ous studies have observed about 35-39% of IGT and 22-
31% of diabetes was undiagnosed in acute heart attack
patients [7-9]. Taken together, these results support the
importance of increasing the early detection of IGT in
the population.
MS has been widely accepted as a predictor of future
diabetes [19-27]. However, the cross-sectional associ-
ation of MS with IGT has not been widely evaluated in
the Chinese population. In our study, MS was associated
with about a 3-fold increase in the risk of IGT. In the
study of Meigs et al., similar results were also observed
among their study population, which included Caucasians,
Mexican-Americans, and African-Americans, where ORs
for IGT of 3–4 were observed [29]. Further, MS has ac-
ceptable power to discriminate subjects with IGT from
those without IGT (AROC about 63%) in this population.
The prevalence of MS defined by the NCEP criteria isTable 3 The effect of clustering of metabolic syndrome compo
Number of
clustering
Prevalence n (%) Number of
Including hyperglycemia 0 189 (20.4) 13 (6.9)
1 200 (21.6) 29 (14.5)
2 230 (24.8) 51 (22.2)
≥3 309 (33.2) 129 (41.7)
Without hyperglycemia
1 178 (27.1) 24 (13.4)
2 169 (25.8) 35 (20.6)
≥3 120 (18.3) 38 (31.7)
Logistic regression was age-and gender-adjusted. IGT; impaired glucose tolerance; Bhigher than that defined by the IDF criteria (33.3% vs.
30.0%) in our study subjects, since central obesity is a pre-
requisite for the IDF definition [30,31]. OR, AROC and
AR% and PAR% are also somewhat higher for the NCEP
criteria than for the IDF criteria (i.e., 3.16, 63.4%, 64.0%,
37.2%, respectively, vs. 2.84, 63.0%, 61.6%, 32.5%, respect-
ively, as shown in Table 2), but the magnitudes are quite
similar. In general, MS, whether defined by the NCEP or
IDF criteria, is useful for identifying OGTT candidates.
Among the single components of MS, hyperglycemia
showed the highest association with IGT with OR (95%
CI) being 2.79 (1.99-3.91), which is very close to MS de-
fined by the IDF criteria (OR = 2.84, 95% CI: 2.03-3.79). In
our previous study in a cohort of 7922 subjects, a much
higher association of hyperglycemia with the future devel-
opment of diabetes was observed (OR about 5.6 for MS
vs. 9.1 for hyperglycemia) [19]. Many other longitudinal
studies, such as Hongkong Study [24] and the Framing-
ham Offspring Study [25] also support the notion that
hyperglycemia is more predictive than MS. The similar as-
sociation of hyperglycemia and MS with IGT in this cross
sectional study can be at least partially explained by the
strong association of IGT with insulin resistance [33,34],
which is the underlying pathophysiology of MS [35].nents on the risk of IGT, determined by logistic regression
IGT (%) OR (95% CI) The combination of metabolic
components in the cluster with
the most prevalent rate of IGT
Ref
1.71 (0.85-3.46) hyperglycemia
2.38 (1.22-4.67) hyperglycemia + high BP
5.92 (3.12-11.21) hyperglycemia + high BP + central obesity
1.53 (0.74-3.19) Central obesity
2.21 (1.08-4.53) Central obesity + high BP
4.44 (2.14-9.20) Central obesity + high BP + high TG
P: blood pressure; TG: triglyceride.
Table 4 The combined effect of waist circumference level and fasting glucose level on the risk of IGTa
Waist circumference
level
FPG <5.6 mmol/l (n = 657) FPG: 5.6-6.0 mmol/l (n = 183) FPG ≥6.1 mmol/l (n = 88)
n1 Prevalence of IGT (%) n2 Prevalence of IGT (%) n3 Prevalence of IGT (%)
1 350 34 (9.7) 66 20 (31.3) 23 12 (43.5)
2 218 52 (23.9) 77 26 (33.8) 33 19 (57.6)
3 89 23 (25.8) 40 19 (47.5) 32 22 (59.4)
aTrend P < 0.0001. IGT: impaired glucose tolerance; FPG: fasting plasma glucose. Waist circumference (WC) level: 1: WC <90 cm for men and <80 cm for women; 2:
WC ≥90 cm but <102 cm for men, and ≥80 cm but <88 cm for women; 3: WC ≥102 cm for men and ≥88 cm for women.
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define hyperglycemia at a fasting glucose level of
≥5.6 mmol/l, and therefore more individuals with this
MS component can be identified [30-32]. However, since
the prevalence of hyperglycemia is lower than that of
MS or the other components in the general population,
especially in Chinese [1,2,36], using fasting glucose alone
is insufficient to identify most IGT individuals [13-16].
At the same time, it is important to recognize that the
metabolic mechanisms that underlie hyperglycemia and
IGT are somewhat different. Specifically, hyperglycemia
is characterized by elevated hepatic glucose output and a
defect in early insulin secretion, while IGT is character-
ized by peripheral insulin resistance. Therefore, there is
limited overlap between the two factors, and they define
different groups of subjects [37].
Many studies have shown that forming clusters
with more metabolic variables than hyperglycemia
alone increases the prediction of diabetes/IGT greatly
[4,6,17,19,20,25]. In this study, we observed that clustering
of any 1, 2, and ≥3 metabolic components gradually
increases the association with the risk of IGT, with OR
(95%CI) being 1.71 (0.85-3.46), 2.38 (1.22-4.67), and 5.92
(3.12-11.21), respectively. Notably, the increased IGT risk
was still observed when hyperglycemia was excluded from
the clustering of metabolic components. Similar findings
have already been reported in other prospective studies,
including ours, which analyzed the association of MS and
its components with the future development of diabetes
[19,20,25].
Central obesity has been suggested as an important
risk factor of insulin resistance [38], and central obesity
has been widely regarded as an important factor in esti-
mating the risk of IGT [19,24,25,29]. In this study, cen-
tral obesity is confirmed to have the ability to identify
IGT subjects, with an OR (95% CI) being 2.06 (1.46-
2.91), which is second highest only to hyperglycemia.
Similar results have also been observed in cohort studies
[19,24]. In this current study, the pattern of interactions
between waist circumference (WC) level and FPG level
were revealed. According to the central obesity criteria
defined for Asians and Westerners [30,31], WC were
classified into 3 levels: 1, waist circumference <90 cm
for men and < 80 cm for women; 2, waist circumference90–101 cm for men, and 80–87 cm for women; 3, waist
circumference ≥102 cm for men and ≥88 cm for women,
respectively. FPG levels were defined as: FPG <5.6 mmol/
l, FPG = 5.6-6.0 mmol/l, and FPG ≥6.1 mmol/l (see
Table 4). The association with IGT is stronger with FPG
level than with WC level. Given a WC level that remained
unchanged, the risk of IGT increased about 15-35% as the
level of FPG increased. Given a FPG level that remained
unchanged, the risk of IGT increased about 7-18% as the
level of WC increased. Clustering these two metabolic
components increased the risk even further. This in-
creased risk of IGT was dramatic when the two variables
were both present at their highest defined levels. Although
the criteria for the definition of central obesity are lower
in the Asians than in the Westerners [30,31], persons with
hyperglycemia and at the higher level of WC, deserve
close scrutiny.
The prevalence of high BP in this population was as
high as 44.7%, and a significant association with IGT
was observed (see Table 2, OR = 1.61, AROC % = 59.1,
AR % = 53.5, PAR % = 34.0). The high prevalence of high
BP may help explain the results in Table 3 which shows
that high BP combined with hyperglycemia in the meta-
bolic clustering to exhibit the highest association with
IGT among clusters of the same number of components.
Since the Chinese population is vulnerable to high BP
[36], these results arouse special concerns when evaluat-
ing the risk of IGT.
It must be mentioned that our study has a few limita-
tion. First, the prevalence of MS in this population was
much higher than that observed in our previous study
(about 20%) and in the general population (9.8% for men
and 17.8% for women) [19,36]. The high prevalence of
MS in this study is consistent with the hypothesis that
this population would be at high risk of MS and diabetes
due to their sedentary working style and high work-
related stress [19,36]. Moreover, health support or
advice has raised awareness of diabetic risk in the
population and may have made more obesity persons
willing to volunteer to participate in this study. Conse-
quently, the results are likely to be less representative
of the general population. However, our findings are
very informative for the high risk individuals, such as
those in this study, to realize the risk of diabetes if they
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its components.
Second, our sample size is not big enough to divide
subjects into groups according to age and gender. Thus
the age- and gender- specific association between factors
and the risk of IGT were not revealed. However, the pur-
pose of this study focuses on whether MS is an effective
method for helping to identify high risk individuals as
early as possible. Based on the findings from this study,
it is confirmed that persons with MS are very likely to
fail OGTT, and IGT can be detected in subjects who
have normal FPG. Furthermore, we found over 60% of
the excess risk of IGT attributable to MS, and about 32-
37% of IGT in the population attributable to MS. These
data suggest that an effective strategy to reduce IGT in-
volves intensive intervention to return MS components
back to normal.
Conclusion
In summary, this study shows that metabolic syndrome
(MS) and its components can be used to evaluate the
risk status of IGT in the growing population of urban
professionals in China. People with MS or its compo-
nents, especially hyperglycemia, central obesity, or with
the cluster of its components are strong candidates for
an oral glucose tolerance test in order to achieve early
detection of IGT. This information should be publicized
in the target population and the medical professionals
who serve this important human resource in China. Fur-
ther research will seek to refine these data to examine
age and gender related issues.
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